Loading
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Latest quote
$65.015
−$1.945 · -2.90%
After-hours
$66.30
+$1.285 · +1.98%
Oct 8, 6:00 PM ET
Regular session · ET · Market data may be delayed.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Day range
Current $65.015
52-week range
Current $65.015
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
34
Expensive
Sentiment
49
Mixed
Risk
40
Moderate Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Day range
Current $65.015
52-week range
Current $65.015
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 794.31M USD | 476.64M USD | 332.34M USD | 169.45M USD | 78.41M USD |
| Selling, general, and administrative | 129.37M USD | 92.9M USD | 60.7M USD | 39.81M USD | 25.26M USD |
| Operating expenses | 923.68M USD | 569.55M USD | 468.04M USD | 232.26M USD | 103.67M USD |
| Interest income | 119.72M USD | 109.99M USD | 62.91M USD | 8.36M USD | 344K USD |
| Interest expense | — | — | — | 2K USD | 7K USD |
| Depreciation and amortization | 24.86M USD | 15.85M USD | 10.17M USD | 9.45M USD | 3.46M USD |
| Operating income | −923.68M USD | −569.55M USD | −468.04M USD | −232.26M USD | −103.67M USD |
| Net income | −766.63M USD | −463.93M USD | −402.27M USD | −223.49M USD | −100.08M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$123.5
89.96% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI279.35M0.01%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM231.67M0.30%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB201.86M0.11%185.3B USD0.03%$287.63+0.23%
State Street SPDR S&P Biotech ETFXBI136.97M1.36%10.08B USD0.35%$149.29-0.63%
Vanguard Morningstar Small-Cap Growth ETFVBK115.85M0.25%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF92.79M0.10%95.4B USD0.05%$233.13-0.15%
T. Rowe Capital Appreciation Equity ETFTCAF78.38M0.86%9.09B USD0.31%$43.20-0.58%
iShares Biotechnology ETFIBB73.65M0.71%10.4B USD0.44%$200.48-1.41%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
